Abstract
The latest recommendations of international cardiology societies have stressed the importance of biological markers: BNP (B-type Natriuretic Peptide) is highlighted as a diagnostic tool for chronic heart failure by the European society of cardiology, and the new definition of myocardial infarction is based on a cut off for cardiac troponin I or T above the 99 th percentile of a healthy volunteer population. The cardiac specificity of the troponin assays are now accepted as being 100%. The reported results of the numerous available commercial troponin I assays will tend towards a standardization as an international reference calibrator become available. They must also take into account the various circulation forms, free or bound, the proportion of which changes over time after the start of the cardiac infarction. The BNP assay is performed either by radio-isotope methods or by an immunofluorimetric method. It can now be done with a short turn around time for emergency cases. These biological blood markers have strong value in the diagnosis, therapy monitoring and prognosis of acute coronary syndromes and of heart failure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
